In order to deliver a personalised, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer. By continuing to use this site and access its features, you are consenting to our use of cookies. To find out more about the way drugeruptiondata.com uses cookies please read our 'Cookie Policy'.
Adverse reactions attributed to entire drug class 'Tyrosine kinase inhibitor'
Please login to view adverse reactions.
Acute febrile neutrophilic dermatosis (Sweet's / Sweet syndrome)
- (2021): Yang JJ+, Dermatol Ther 34(1), e14461 (14 cases) [REVIEW]
Cutaneous adverse reaction (includes severe cutaneous adverse drug reaction (SCAR))
- (2022): Barbieri MA+, Front Oncol Nov (e-Collection) 58%
- (2019): Clapes V+, Pharmaceut Med 33(1), 2123%
Cutaneous toxicity / skin toxicity
- (2015): Macdonald JB+, J Am Acad Dermatol 72(2), 203 [REVIEW]
- (2016): Yu L+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 37(11), 92944%
- (2018): Sanmartin O, Curr Probl Dermatol 53, 93
Hand–foot syndrome (palmar–plantar erythrodysesthesia)
- (2023): Yeh CN+, Biol Trace Elem Res Mar, Online ahead of print [REVIEW]
- (2018): Sanmartin O, Curr Probl Dermatol 53, 93
- (2022): Park JS+, J Eur Acad Dermatol Venereol Sep, Online ahead of print [REVIEW] (association)
- (2016): Yu L+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 37(11), 92919%
- (2022): Khoshnam-Rad N+, Anticancer Drugs 33(1), e1-e8 (15 cases)
- (2016): Yu L+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 37(11), 92914%
- (2014): Prescrire Int 23(151), 180
- (2021): Cheng M+, Front Cardiovasc Med Nov (e-Collection) [REVIEW]
- (2020): Gadd M+, Cancer Rep (Hoboken) Aug, e1275
- (2014): Fallahi P+, Expert Opin Drug Saf 13(6), 723 [REVIEW]
- (2024): Luna NA+, J ASEAN Fed Endocr Soc 39(2), 20-2640%
- (2023): Leo S+, Ann Endocrinol (Paris) Mar, Online ahead of print [REVIEW]
- (2017): Rizzo LFL+, Medicina (B Aires) 77(5), 394
- (2016): Yu L+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 37(11), 92912%
Gastrointestinal adverse reaction
- (2023): Zhang P+, Therap Adv Gastroenterol Apr (e-Collection) [REVIEW]
Gastrointestinal disorder / discomfort
- (2022): Barbieri MA+, Front Oncol Nov (e-Collection) 34%
- (2019): Clapes V+, Pharmaceut Med 33(1), 2117%
- (2016): Yu L+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 37(11), 92932%
Hepatic (liver) disorder / hepatobiliary disorder / hepatic (liver) dysfunction
- (2022): Barbieri MA+, Front Oncol Nov (e-Collection) 14%
Hepatotoxicity / liver injury / acute liver injury / drug-induced liver injury (DILI)
- (2019): Carretero-Gonzalez A+, Medicine (Baltimore) 98(47), e18098 (3 cases) (previous treatment with immune checkpoint inhibitors also implicated)
- (2016): Yu L+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 37(11), 92912%
- (2015): Karczmarek-Borowska B+, Contemp Oncol (Pozn) 19(2), 87 [REVIEW]
- (2016): Yu L+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 37(11), 9298%
- (2016): Yu L+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 37(11), 92938%
- (2014): Fallahi P+, Expert Opin Drug Saf 13(6), 723 [REVIEW]
- (2016): Yamada M+, Rinsho Ketsueki 57(4), 489
- (2016): Yu L+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 37(11), 92919%
Eyelashes – hypertrichosis (eyelash megalotrichosis)
- (2024): Gershon R+, PLoS One 19(12), e0313326 [REVIEW]
Nephrotoxicity / kidney injury / acute kidney injury (AKI) / drug-induced kidney injury
- (2023): Collotta D+, G Ital Nefrol (Italian) 40(Suppl 81), 2023-S81 [REVIEW]
- (2022): Barbieri MA+, Front Oncol Nov (e-Collection) 10%
- (2019): Clapes V+, Pharmaceut Med 33(1), 2112%
Adverse effects / adverse reactions
- (2025): Kyriacou NM+, Clin Transl Sci 18(5), e70224 [REVIEW]
- (2023): Boskabadi SJ+, J Oncol Pharm Pract May, Online ahead of print [REVIEW]
- (2022): Barbieri MA+, Front Oncol Nov (e-Collection) 16%
